Craniopharyngioma is a slow-growing, non-cancerous brain tumor located near the pituitary and hypothalamus. Despite its low incidence and classification as WHO grade I, its position in the saddle area complicates surgical intervention, leading to higher perioperative risks and poorer patient outcomes. Alfa Cytology is committed to pioneering new therapeutic approaches for craniopharyngioma treatment for our clients.
Introduction to Craniopharyngioma
Craniopharyngioma (CP) primarily manifests in two histological forms: adamantinomatous craniopharyngioma (ACP) and papillary craniopharyngioma (PCP). ACP is predominantly found in children and exhibits a bimodal age distribution, while PCP is more common in adults. The distinct genetic profiles of these tumors are characterized by specific mutations; ACP is often associated with activating mutations in the CTNNB1 gene (β-catenin), whereas PCP is linked to BRAF-V600E mutations.
Fig.1 Features of craniopharyngioma. (Müller, H. L., et al., 2019)
Therapeutic Development for Craniopharyngioma
The therapeutic landscape for craniopharyngioma has evolved significantly, with advances in surgical techniques, radiotherapy, and targeted therapies. Traditional management primarily involves surgical resection, which aims to achieve gross total resection (GTR) or subtotal resection (STR) followed by radiotherapy. While surgery can alleviate symptoms and reduce tumor burden, complete resection is often complicated by the tumor's invasive nature and proximity to critical neural structures.
We summarize here current treatments and relevant clinical trials for craniopharyngioma.
|
NCT |
Targets |
Therapeutics |
Phase |
| NCT03224767 |
BRAF/MEK |
Vemurafenib + Cobimetinib |
|
| NCT05465174 |
PD-1+ pan-RAF-kinase |
Nivolumab + Tovorafenib |
|
| NCT05233397 |
IL-6 receptor |
Tocilizumab |
|
| NCT06217848 |
GLP-1 |
Saxenda |
|
Our Services
At Alfa Cytology, we offer a comprehensive range of services designed to facilitate craniopharyngioma diagnostics and therapy development. Our team provides extensive support throughout the drug development process, from initial screening of compounds to detailed pharmacokinetic and pharmacodynamic studies.
Case Study - Papillary Craniopharyngioma (PCP) PDX Model
Model Introduction
The PCP PDX model provides a clinically relevant platform for evaluating targeted therapies for PCP, particularly for BRAFv600e-negative tumors that do not respond to conventional BRAF inhibitors. This model recapitulates the key pathological and molecular features of human PCP, enabling preclinical assessment of novel therapeutic agents.
Model Information
Model Details
- Model: Papillary Craniopharyngioma (PCP) PDX Model
- Animal: Nude Mice
- Weight: 18-20 g
Patient Information
- Sex: Female
- Race/Ethnicity: N/A
- Treatment: Surgical Resection
- Age: N/A
- Diagnosis: Papillary Craniopharyngioma (BRAFv600e-)
Model Construction
The PCP PDX model was established by stereotaxic implantation of primary PCP cells into the brains of nude mice. Primary cells were isolated from fresh PCP tumor tissues obtained during surgical resection, enzymatically digested with hyaluronidase and collagenase type I, and then injected into mouse brains. Tumor growth was monitored by MRI-T2WI at 8 weeks post-implantation.
Fig. 2 Workflow of PCP PDX model establishment. (Source: Alfa Cytology)
In Vivo Efficacy Evaluation
This study employs the established orthotopic PCP PDX model to evaluate the therapeutic efficacy of drug A, a PDGFR inhibitor, against BRAFv600e- tumors and compare it with the BRAF inhibitor drug B.
- Drug A Therapy: Drug A demonstrates significant tumor growth inhibition in BRAFv600e- PCP PDX models, with marked tumor shrinkage observed on MRI and complete disappearance of squamous epithelium by day 7.
- Drug B Therapy: Drug B shows no therapeutic effect in BRAFv600e- PCP PDX models, with tumors continuing to grow and squamous epithelium remaining intact, identical to control mice.
Fig. 3 Anti-tumor efficacy of drug A and drug B in PCP PDX models. Data are presented as mean ± SEM. Data are presented as mean ± SEM. (Source: Alfa Cytology)
Contact Us
For inquiries about our services or to discuss collaboration opportunities in the field of craniopharyngioma research, please reach out to Alfa Cytology. Our dedicated team is ready to assist you in advancing your therapeutic innovations. For further details, please
reach out to our team for comprehensive information and assistance.
References
- Müller, H.L.; et al. (2019). Craniopharyngioma[J]. Nat Rev Dis Primers. 5, 75.
- Agosti E.; et al. (2024). Advancing Craniopharyngioma Management: A Systematic Review of Current Targeted Therapies and Future Perspectives[J]. International Journal of Molecular Sciences. 25(2): 723.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
